Select Page ::

Parkinsons disease: Everything you need to know about the neurological disorder – The Indian Express

Posted on November 13, 2020 by Danzig

By: Lifestyle Desk | New Delhi | Updated: November 10, 2020 2:11:57 pmIt is important to keep a track of the symptoms of Parkinson's disease. (Source: Getty Images/Thinkstock)

Parkinsons disease is one of the most common neurological disorders which prevails most in the elderly age group. It is a condition in which a patient holds limited or no control over his movements and body balance. It occurs and progresses with ageing, but in rare cases, it is also witnessed among children and teenagers as well. Also, men are more prone to Parkinsons disease than women, says Dr Rajul Aggrawal, senior consultant, neurologist, Sri Balaji Action Medical Institute, New Delhi who further discusses Parkinsons disease in detail.

As a disease of the central nervous system characterised by difficulty in movements, Parkinsons has four main symptoms, namely tremors, stiffness, postural instabilities, and slowness of movements. Parkinsons disease is a degenerative disease of the brain as a result of which brain neurons are unable to produce dopamine. When dopamine reduces in the brain, it causes the emergence of symptoms of Parkinsons. Parkinsons is a progressive disease though the rate of deterioration may vary in different individuals.

Though causes of Parkinsons are mainly unknown several factors may appear to play a role.

*Genetic Factors: Researchers have identified several genes responsible for Parkinsons but these are rare except in cases where several family members are affected by Parkinsons disease.*Exposure to certain toxins or environmental factors may increase the risk of Parkinsons disease but the risk is relatively less.*Men are 50 per cent more likely to be affected by Parkinsons than women.*Most people develop Parkinsons after 60 years of age. Though 5 to 10 per cent can develop Parkinsons before the age of 50 years. This condition is called early-onset disease which is often but not always inherited.*Parkinsons patients may also experience other symptoms such as difficulty in swallowing, chewing, speaking, urinary problems, constipation, skin problems, depression, emotional changes and sleep disruption. They may occur much before the appearance of cardinal motor symptoms.

ALSO READ | Stan Swamy files plea for straw, sipper in jail; court seeks NIA reply

Early Parkinsons symptoms are subtle and occur gradually. They may be taken as signs of normal ageing, for example, mild tremors, difficulty in getting up from a chair, spending more time in the bathroom, speaking softly, writing becoming small, slow and cramped, lack of facial expressions, stiffness in shoulder joints and knee joints. People also develop a Parkinsons gait that includes a tendency to lean forward, small quick steps as if hurrying forward, reduced swing of arms. They also may have trouble initiating or continuing movements.Usually, Parkinsons starts on one side of the body, in either upper or lower limb and gradually progresses to the other limbs.Currently, no blood laboratory or radiological tests are available to diagnose Parkinsons disease. It is a clinical diagnosis based on history and examination findings. Neurologists may do certain tasks to rule out secondary causes of Parkinsons.

Parkinsons-like symptoms may be found in other degenerative diseases and neurologists would be able to differentiate these from Parkinsons disease.Parkinsons patients should be more cautious about their disease, mentioned Dr Aggarwal.

*Take medicines regularly and manage other daily tasks accordingly.*Never hesitate to seek others help and cooperation in need.*Keep sharing about your situation with loved ones and ask for help or suggestions to get certain work done if they are not available. Do not to hesitate and feel low about your condition.

*Generally our senior citizens need extra care in this regard. Keep a check on the development of the physical symptoms and seek doctors suggestion. Take good care of elderly family members.*Never miss any prescribed medicine suggested by the doctor. Patients may also be on therapies, hence go for them at scheduled times.*Keep a positive outlook toward life and manage daily tasks accordingly. Most of all, refrain from taking stress as it is only going to add to the problems.*Stay away from habits like smoking, alcohol intake, etc.*Lead a healthy lifestyle, keep the nutrition value high, and go for timely check-ups.

For more lifestyle news, follow us: Twitter:lifestyle_ie|Facebook:IE Lifestyle| Instagram:ie_lifestyle

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Lifestyle News, download Indian Express App.

IE Online Media Services Pvt Ltd

Read the rest here:
Parkinsons disease: Everything you need to know about the neurological disorder - The Indian Express

Interventional Neurology Device Market: Technological Advancement & Growth Analysis with Forecast to 2025 – Eurowire

Posted on November 13, 2020 by Danzig

Overview Of Interventional Neurology Device Industry 2020-2025:

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The Interventional Neurology Device Market analysis summary by Reports Insights is a thorough study of the current trends leading to this vertical trend in various regions. Research summarizes important details related to market share, market size, applications, statistics and sales. In addition, this study emphasizes thorough competition analysis on market prospects, especially growth strategies that market experts claim.

Interventional Neurology Device Market competition by top manufacturers as follow:MedtronicJohnson and JohnsonTerumo CorporationPenumbra, Inc.Merit Medical Systems, IncW.L. Gore & AssociatesMicroport Scientific CorporationMedikit Co., Ltd.Stryker

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/176258

The global Interventional Neurology Device market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights.

The Type Coverage in the Market are: Embolization & coilingNeurothrombectomy Devices

Market Segment by Applications, covers:Treatment of Cerebral AneurysmsTreatment of Cerebral VasospasmVertebroplasty

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Major factors covered in the report:

To get this report at a profitable rate.: https://reportsinsights.com/discount/176258

The analysis objectives of the report are:

Our report offers:

Market share assessments for the regional and country level segments. Market share analysis of the top industry players. Strategic recommendations for the new entrants. Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets. Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations). Strategic recommendations in key business segments based on the market estimations. Competitive landscaping mapping the key common trends. Company profiling with detailed strategies, financials, and recent developments. Supply chain trends mapping the latest technological advancements.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://reportsinsights.com/industry-forecast/Interventional-Neurology-Device-Market-176258

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Read this article:
Interventional Neurology Device Market: Technological Advancement & Growth Analysis with Forecast to 2025 - Eurowire

New cell may be solution to treating incurable neurological diseases – OSU – The Lantern

Posted on October 31, 2020 by Danzig

Researchers at The Ohio State University Wexner Medical Center have discovered a new immune cell that not only protects the brain and spine from further damage but also encourages nerve cells to regrow, which is unprecedented. Credit: Courtesy of the Wexner Medical Center at Ohio State

Researchers at Ohio State and the University of Michigan discovered a new immune cell that may hold the key to treating incurable neurological diseases such as multiple sclerosis, traumatic brain and spine injuries, and strokes.

The cell releases a substance that stimulates nerve cell growth and allows damaged nerve fiber to regenerate while many other immune cells remove damaged cells Dr. Andrew Sas, an assistant professor of neurology at Ohio State, said. Researchers found the cell after discovering a similar cell in a mouse model.

Sas said this unique ability to save dying nerve cells and grow new ones is important for patients who have difficulty speaking, moving, seeing, feeling and even thinking due to these diseases and injuries.

They are quality of life things, because if you cant use an arm or a leg or you cant talk to others, then you can imagine how much more difficult that life is then compared to all the things that you can do and we take for granted, Sas said. Unfortunately, patients who have neurologic injuries live with a lifetime of disability.

In 2014, there were about 2.5 million traumatic brain injury-related emergency department visits and 56,800 deaths in the U.S. more than 810,000 of the visits and 2,500 of the deaths were children, according to the Centers for Disease Control and Prevention. Neurological diseases also burden many nearly one million people are estimated to have multiple sclerosis in the U.S., according to the National Multiple Sclerosis Society, and about 5,000 people in the U.S. are diagnosed with ALS each year, according to the CDC.

The newly discovered cell is a type of white blood cell called a granulocyte. Dr. Benjamin Segal, professor and chair of the Department of Neurology and director of Ohio States Neuroscience Research Institute, said it resembles an immature neutrophil a plentiful white blood cell in our bloodstream that normally helps fight off infection but is unique.

This is an unusual, neutrophil-like cell. It has features of a more immature stage, but hasnt been described before, Segal said. It expresses certain genes and molecules on its surface that are not normally associated with neutrophils or granulocytes. But some of the markers that they express had been associated with healing processes.

Sas said when researchers injected these cells into mice, they protected damaged nerve cells and enabled nerve fiber growth. In order to see these effects, Sas said an antibody is used to block mature neutrophil cells already present that can stunt the recovery process, allowing a greater production of this new cell.

One of the things that was really important about our discovery is that by blocking mature neutrophils, we actually can enrich this immature population and make it more prevalent so that it has a bigger impact, Sas said. This way, we were able to get more of those cells so that they could have a better, more beneficial response.

Segal said the researchers next step is to identify the cell in people with traumatic brain injuries and manipulate the cell in the same way as in the mouse model.

Sas said they hope to inject the cells into human patients and see the same effects, potentially paving the way for new treatment options.

Its exciting that we have a new line of research and possible therapies that could be coming down the line in the future, that could help [patients] because today, we dont have a lot of therapies, Sas said. Were on the right path to, hopefully, giving patients in the future hope that theyre gonna do better than the patients before them.

Study findings were published Monday in Nature Immunology. The research was funded by the National Eye Institute, National Institutes of Health, the Wings of Life Foundation and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, according to a press release.

Read the original here:
New cell may be solution to treating incurable neurological diseases - OSU - The Lantern

UB researcher narrows time window for administering specific treatment to infants with Krabbe disease – UB Now: News and views for UB faculty and…

Posted on November 13, 2020 by Danzig

A team of UB researchers has published a paper in Nature Communications that is helping to define the best time to give a specific treatment to infants born with Krabbe disease (KD). This treatment has been found to prolong life for these infants for as long as a few years.

The paper was published online in Nature Communication Oct. 23.

Daesung Shin, assistant professor in the Department of Biotechnical and Clinical Laboratory Sciences and the Neuroscience Program, both in the Jacobs School of Medicine and Biomedical Sciences at UB, is the lead investigator. He also conducts research at UBs Hunter James Kelly Research Institute.

KD is an inherited disorder that destroys myelin, the protective coating of nerve cells in the brain and throughout the nervous system. In most cases, signs and symptoms of Krabbe disease develop in babies before 6 months of age, and the disease usually results in death by age 2. When it develops in older children and adults, the course of the disease can vary greatly.

The progressive neurologic disorder is caused by a deficiency of galactosylceramidase (GALC). GALC is an enzyme that breaks down galactosylceramide, an important component of myelin, which ensures the rapid transmission of nerve impulses.

Although there is no cure for KD, hematopoietic stem cell therapy (HSCT), a therapy that makes blood cells, reduces neurologic deterioration and improves developmental advances. These benefits are dependent on the severity of the disease at the time the stem cells are transplanted, and are only beneficial if delivered at a clinically defined pre-symptomatic time point before symptoms appear.

Even though it is widely accepted that early treatment is essential for the most positive outcome, the precise therapeutic window for treatment and what happens during this early time have never been elucidated, Shin says.

To address that issue, his team used mutations to create a novel mouse model of KD.

We engineered an inducible knockout mouse for the GALC gene deletion in specific cells at specific times, which provided us with the opportunity to directly ask when and where GALC enzyme is required for brain development, Shin explains.

We were particularly interested in the role of early developmental GALC function, he says. Our study not only revealed a key developmental process that requires GALC in the perinatal period, but also demonstrated that temporal GALC expression is likely a major contributor to brainstem development.

The researchers found that by increasing GALC levels at or before this newly defined perinatal period they could improve the effectiveness of therapeutic interventions for KD.

For the first time, our work showed the mechanistic evidence to explain why treatment must occur so early, with the defined critical postnatal period at days 4-6 in mice, and demonstrated that temporal GALC expression during this time is a major contributor to brainstem development, Shin says. Augmenting GALC levels at or prior to this newly defined period would likely improve the efficacy of therapeutic interventions for Krabbe patients.

While the time scale between mice and humans is considerably different, the sequence of key events in brain maturation between the two is consistent, he notes. It was estimated that the mouse nervous system at postnatal days 4-6 corresponds to a gestational age of 32 weeks in humans. Therefore, we anticipate that if our result is correct, then in utero treatments at, or prior to, 32 weeks should have better outcomes than conventional postnatal treatment for Krabbe babies.

Shin says his team will further identify which cell type needs to be targeted with therapy.

This work will directly impact the design of novel treatment options for KD patients, he says, noting that KD studies are at the basis of research on other, more common neurodegenerative diseases, such as multiple sclerosis and Parkinsons disease. Therefore, the teams work will have implications beyond KD.

Co-authors on the research were Nadav I. Weinstock, MD-PhD student, and Conlan Kreher, former masters student, both of the HJKRI and the Department of Biochemistry in the Jacobs School; Jacob Favret, research technician in the Department of Biotechnical and Clinical Laboratory Sciences; Lawrence Wrabetz and M. Laura Feltri, both co-directors of the HJKRI and members of the departments of Biochemistry and Neurology, as well as the Neuroscience Program.

Duc Nguyen and Ernesto R. Bongarzone of the Department of Anatomy and Cell Biology in the College of Medicine at the University of Illinois at Chicago also participated in the research.

The project was initiated with the support from Empire State development fund for HJKRI, and further developed and finalized by the R01, R56 and R03 grants from National Institutes for Health-National Institute for Neurological Disorders and Stroke awarded to Shin.

Read the original post:
UB researcher narrows time window for administering specific treatment to infants with Krabbe disease - UB Now: News and views for UB faculty and...

Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development – DocWire News

Posted on October 31, 2020 by Danzig

This article was originally published here

Int J Infect Dis. 2020 Oct 27:S1201-9712(20)32247-5. doi: 10.1016/j.ijid.2020.10.044. Online ahead of print.

ABSTRACT

OBJECTIVES: To analyze the cerebrospinal fluid (CSF) of patients with SARS-CoV-2 infection and neurological manifestations to provide evidence for the understanding of mechanisms associated with central nervous system (CNS) involvement in COVID-19.

METHODS: Patients (n = 58) were grouped according to their main neurological presentation: headache (n = 14); encephalopathy (n = 24); inflammatory neurological diseases, including meningoencephalitis (n = 4), acute myelitis (n = 3), meningitis (n = 2), acute disseminated encephalomyelitis (ADEM) (n = 2), encephalitis (n = 2), and neuromyelitis optica (n = 1); and Guillain-Barr syndrome (n = 6). Data about age, sex, cerebrovascular disease, and intracranial pressure were evaluated in combination with CSF profiles defined by cell counts, total protein and glucose levels, concentration of total Tau and neurofilament light chain (NfL) proteins, oligoclonal band patterns, and detection of SARS-CoV-2 RNA.

RESULTS: CSF of patients with inflammatory neurological diseases was characterized by pleocytosis and elevated total protein and NfL levels. Patients with encephalopathy were mostly older men (mean age of 61.0 17.6 years) with evidence of cerebrovascular disease. SARS-CoV-2 RNA in CSF was detected in 2 of 58 cases: a patient with refractory headache, and another who developed ADEM four days after COVID-19 symptoms onset. Three patients presented intrathecal IgG synthesis, and four had identical oligoclonal bands in CSF and serum, indicating systemic inflammation.

CONCLUSION: Patients with neurological manifestations associated with COVID-19 had diverse CSF profiles, even within the same clinical condition. Our findings indicate a possible contribution of viral replication on triggering CNS infiltration by immune cells and the inflammation promoting neuronal injury.

PMID:33127503 | DOI:10.1016/j.ijid.2020.10.044

Go here to see the original:
Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development - DocWire News

Neurology Software Market Is Expected To Reach Multimillion Usd By The End Of 2025 With a Healthy Cagr Rate: Neurology Software are: Epic, Brainlab,…

Posted on October 31, 2020 by Danzig

Introduction and COVID-19 Impact AnalysisGlobal Neurology Software Market report is an easy and convenient information hub to obtain access to highly discernable market related developments across domains and verticals, geographical growth spots as well as technological milestones and product-based segmentation that collectively initiate eventful developments in Global Neurology Software Market.

Our versatile teams of in-house research experts and professionals have laid out elaborate deductions about the growth trajectory of the Global Neurology Software Market on the basis of dedicated research initiatives, adhering to international research standards such as PESTEL and SWOT analysis.

Get a sample of the report @ https://www.orbisresearch.com/contacts/request-sample/4162760

Expert research opinion by our in-house research teams also opine after stringent primary and secondary research endeavors that the Global Neurology Software Market has demonstrated lush growth and revenue stability in past years, and is thus likely to further continue with the trends in the upcoming years. This suggests that the Global Neurology Software Market, despite significant market dents owing to unprecedented COVID-19 outrage is anticipated to recover at optimistic CAGR percentage.

The Major Players Covered in Global Neurology Software Market are:The major players covered in Neurology Software are: Epic, Brainlab, healthfusion, Athenahealth, Practice Fusion, Nextgen, Bizmatics, Greenway Health, Allscripts, Kareo, Advanced Data Systems, NueMD, etc.

Global Neurology Software Market by Type:By Type, Neurology Software market has been segmented into Advanced Neurology EMR Software, Other, etc.

Global Neurology Software Market by Application:By Application, Neurology Software has been segmented into Hospitals, College & Research Institutes, Other, etc.

Market segment by Regions/Countries, this report covers

United StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

Read complete report @

Gauging through Segmentation: Global Neurology Software Market

Key Takeaways from the Report

For Enquiry before buying report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4162760

The concluding sections of the report analyzing nitty gritty of Global Neurology Software Market evaluates the market in terms of end-use applicability and scope of applications of the range of products that align with the needs of end-user needs and expectations. These vivid information about the minutest details of the Global Neurology Software Market is in place to induce logical business discretion.

About Us:Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: ++91 895 659 5155

View original post here:
Neurology Software Market Is Expected To Reach Multimillion Usd By The End Of 2025 With a Healthy Cagr Rate: Neurology Software are: Epic, Brainlab,...

The Role of Ketamine Infusion for Patients with MS-Related Fatigue – Neurology Advisor

Posted on October 31, 2020 by Danzig

Low dose ketamine infusion may be a safe and tolerable treatment strategy for multiple sclerosis (MS)-related fatigue, according to study results published in Multiple Sclerosis Journal.

Chronic fatigue is a very common and disabling symptom of MS, but the pathophysiological mechanisms are poorly understood and there are no effective medications approved by the U.S. Food and Drug Administration for the treatment of MS-related fatigue. The objective of the current study was to assess the safety, tolerability, and efficacy of low-dose ketamine infusion for the treatment of MS-related fatigue.

This double-blind, randomized, active-placebo-controlled study included 18 patients with MS, recruited between February and August 2019 through advertisements and physician referrals from the Johns Hopkins Multiple Sclerosis Center. Participants were between 18 and 65 years old and were randomized to a ketamine (12 patients) or midazolam (6 patients) infusion. The primary study outcome was change in Daily Fatigue Severity for 7 days following a single intravenous infusion of low-dose ketamine (0.5 mg/kg) or midazolam (0.05 mg/kg).

There was no change in Daily Fatigue Severity score during the first 7 days following infusion (-0.10 points; 95% CI, -0.32 to 0.12; P =.40). Additionally, there was no difference between the ketamine and midazolam groups regarding the trajectory of this score during the first 7 days following infusion (P =.40), indicating that low-dose ketamine infusion did not show statistically significant improvement in fatigue severity.

However, when MS-related fatigue was assessed using Fatigue Severity Scale, there was a trend in reduced Fatigue Severity Scale score at 1 week (-5.2 points; 95% CI, -10.4 to 0.14; P =.06). Furthermore, there was a clinically and statistically significant reduction in Modified Fatigue Impact Scale score at day 28 (-13.5 points; 95% CI, -25.0 to -1.98; P =.04).

The study had several limitations, including the pilot nature, relatively small sample size, negative results on the primary outcome, and the use of the Daily Fatigue Score, which was not a validated tool for MS fatigue research, as the primary outcome.

The study researchers concluded that although the primary outcome of this study was negative, because ketamine infusion was associated with large, clinically significant and long-lasting changes in well-validated and multidimensional fatigue measures, we think these results can be the basis for performing a larger study of ketamine or other glutamate modulating agents for MS-related fatigue.

Reference

Fitzgerald KC, Morris B, Soroosh A, et al. Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosisrelated fatigue. Mult Scler. Published online July 7, 2020. doi:10.1177/1352458520936226

Here is the original post:
The Role of Ketamine Infusion for Patients with MS-Related Fatigue - Neurology Advisor

Oilseed Rape Seed Market: Information, Figures and Analytical Insights 2020-2025 – PRnews Leader

Posted on October 31, 2020 by Danzig

This report also researches and evaluates the impact of Covid-19 outbreak on the Oilseed Rape Seed industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Oilseed Rape Seed and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Global Oilseed Rape Seed Market Overview:

The research report, titled [Global Oilseed Rape Seed Market 2020 by Company, Regions, Type and Application, Forecast to 2025], presents a detailed analysis of the drivers and restraints impacting the overall market. Analysts have studied the key trends defining the trajectory of the market. The research report also includes an assessment of the achievements made by the players in the global Oilseed Rape Seed market so far. It also notes the key trends in the market that are likely to be lucrative. The research report aims to provide an unbiased and a comprehensive outlook of the global Oilseed Rape Seed market to the readers.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2821011&source=atm

Global Oilseed Rape Seed Market: Segmentation

For clearer understanding of the global Oilseed Rape Seed market, analysts have segmented the market. The segmentation has been done on the basis of application, technology, and users. Each segment has been further explained with the help of graphs figures. This breakdown of the market gives the readers an objective view of the global Oilseed Rape Seed market, which is essential to make sound investments.

Segment by Type, the Interventional Neurology Device market is segmented intoEmbolization & coilingNeurothrombectomy Devices

Segment by Application, the Interventional Neurology Device market is segmented intoTreatment of Cerebral AneurysmsTreatment of Cerebral VasospasmVertebroplasty

Regional and Country-level AnalysisThe Interventional Neurology Device market is analysed and market size information is provided by regions (countries).The key regions covered in the Interventional Neurology Device market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

To understand the changing political scenario, analysts have regionally segmented the market. This gives an overview of the political and socio-economic status of the regions that is expected to impact the market dynamic.

Global Oilseed Rape Seed Market: Research Methodology

To begin with, the analysis has been put together using primary and secondary research methodologies. The information has been authenticated by market expert through valuable commentary. Research analysts have also conducted exhaustive interviews with market-relevant questions to collate this research report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2821011&source=atm

Global Oilseed Rape Seed Market: Competitive Rivalry

The research report also studied the key players operating in the global Oilseed Rape Seed market. It has evaluated and elucidated the research and development statuses of these companies, their financial outlooks, and their expansion plans for the forecast period. In addition, the research report also includes the list of strategic initiatives that clearly explain the achievements of the companies in the recent past.

Competitive Landscape and Interventional Neurology Device Market Share AnalysisInterventional Neurology Device market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Interventional Neurology Device business, the date to enter into the Interventional Neurology Device market, Interventional Neurology Device product introduction, recent developments, etc.The major vendors covered:MedtronicJohnson and JohnsonTerumo CorporationPenumbra, Inc.Merit Medical Systems, IncW.L. Gore & AssociatesMicroport Scientific CorporationMedikit Co., Ltd.Stryker

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2821011&licType=S&source=atm

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Oilseed Rape Seed market

Chapter 2: Evaluating the leading manufacturers of the global Oilseed Rape Seed market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Oilseed Rape Seed market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

ResearchMoz

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Read this article:
Oilseed Rape Seed Market: Information, Figures and Analytical Insights 2020-2025 - PRnews Leader

A Global Push to Increase Awareness, Action and Access to Thrombectomy Care for Stroke Patients is Underway – PR Newswire India

Posted on October 31, 2020 by Danzig

The Society of Vascular and Interventional Neurology together with MT2020 will distribute a report detailing their global initiative to reduce death and disability in stroke patients

MIAMI, Oct. 29, 2020 /PRNewswire/ --Mission Thrombectomy 2020+ (MT2020+), a global campaign of SVIN (Society of Vascular and Interventional Neurology), has just published "Mechanical Thrombectomy for Acute Stroke. Building Thrombectomy Systems of Care in Your Region: Why and How," a White Paper targeted towards health policymakers. The paper examines the widespread inaccessibility and geographical disparities in receiving Mechanical Thrombectomy (MT), an interventional treatment that has been proven to have overwhelming benefit for a common type of disabling stroke in multiple large studies across many countries since 2015. MT needs to be performed within the first 24 hours of the onset of stroke symptoms for disabling stroke from a large artery being suddenly blocked in the brain (commonly called LVO stroke), and its outcomes are highly time-sensitive, especially early on. The White Paper report calls for sweeping increase in MT awareness, accessibility, and action on a worldwide level. It will be distributed on Oct. 29to coincide with World Stroke Day.

Currently, the United States is a global leader in MT patient care, but the burden of care is almost 4-5 times greater in many lower to middle income countries. According to MT2020, the data on stroke patients and the level of care they receive are as follows.

"Large vessel occlusion stroke is a long-standing silent global crisis that now has a highly effective solutionsince the last fiveyears: Mechanical Thrombectomy. However, thrombectomy care isn't widely accessible with colossal geographic disparities on a global level," said Dr. Dileep Yavagal, MT2020 Chair and GEC Co-Chair and Past-President of SVIN. "We are calling on public health policymakers to increase physical, financial and diagnostic access to thrombectomy for patients with disabling stroke to prevent a lifetime of suffering and death."

The White Paper also provides perspective on:

The White paper will be disseminated in all six continents by the 82 Regional Committees of MT2020. The long-term goal is the emergence and wide-spread availability of Mechanical Thrombectomy as the standard of care globally. While progress has been made since the formation of MT2020 in 2016, there is still an imminent need for continued efforts.

About Mission Thrombectomy 2020 (MT2020)

Mission Thrombectomy 2020+ is a global health campaign, founded by the Society of Vascular and Interventional Neurology (SVIN) in 2016, to accelerate access to the stroke thrombectomy surgery globally. The goal of MT2020 is to coalesce global public health efforts with a goal to double access to thrombectomy every two years for stroke caused by large vessel occlusion (LVO). The campaign will improve stroke care worldwide by increasing the rate of stroke thrombectomy for eligible patients from less than 100,000 procedures today to 202,000 annually by end of 2020 and thereby reduce global stroke disability. Stroke Thrombectomy, also known as Mechanical Thrombectomy, is the new highly effective standard of care that reverses paralysis from a stroke in over 60% of patients if done by experts within sixhours of stroke symptoms. For further information about MT2020, please visit http://missionthrombectomy2020.org.

About SVIN

The Society of Vascular and Interventional Neurology was created to achieve the highest level of care for patients through increased collaboration in scientific research and by educating young professionals and training young investigators. The Society also aims to provide opportunities to connect leaders in the field and provide a common ground for dialogue and creation of practice and safety standards. Our mission is to represent the advancement of interventional neurology as a field with the ultimate goal of improving clinical care and outcomes in patients with stroke and cerebrovascular diseases. For further information about SVIN, please visit http://www.svin.orgor find us on Facebook, Twitter, or LinkedIn.

For more information about MT2020, contact Dileep Yavagal at [emailprotected].

Shift towards Orphan Drugs is Anticipated to Drive Demand Growth in Rare Neurological Disease Treatm – PharmiWeb.com

Posted on December 8, 2021 by Danzig

250 Pages Rare Neurological Disease Treatment Market Survey by Fact MR, A Leading Business and Competitive Intelligence Provider

According to Fact MRs recent market research,sales of Rare Neurological Disease Treatmentto swell at propelled CAGR through2031, as investment towards expansion of healthcare infrastructure continues rising. The goal of the survey is uncover growth opportunities, key trends, growth drivers, and challenges. It also provides recommendations to assist businesses in preparing for unforeseen challenges.

Focus on improving overall patient care will remain a chief growth driver. Besides this, Rare Neurological Disease Treatment market will continue gaining from increasing willingness among patients and families to spend on advanced healthcare.

To remain ahead of your competitors, request for a sample https://www.factmr.com/connectus/sample?flag=S&rep_id=4594

To offer an in-depth overview, the report provides sales projections for over 20 countries. It also identifies segments exhibiting maximum growth.

Digital Transformation in Healthcare Presenting Opportunities for Rare Neurological Disease Treatment Market Growth

Healthcare organizations around the world are deploying digital tools to accommodating changing consumer preferences. They are pressing on solving the long-standing challenge pertaining to care model innovation.

Considering this, the focus on making healthcare affordable and more transparent will increase. Adoption of care model innovation in healthcare will have a profound impact on the Rare Neurological Disease Treatment market.

The market study done by Fact.MR gives exclusive information about how the market will grow. The study identifies crucial trends that are determining the growth of Rare Neurological Disease Treatment market. This newly published report sheds light on vital dynamics, such as the drivers, restraints, and opportunities for key market players as well as emerging players associated with the production and supply. The latest report by Fact.MR provides detailed Market Analysis of Rare Neurological Disease Treatment

The report offers actionable and valuable market insights of Rare Neurological Disease Treatment. The latest report by Fact.MR provides details on the present scenario of the market across various regions along with the historic data and forecast of the market. The report also includes information on the sales and demand of Rare Neurological Disease Treatment Market across various industries and regions.

This newly published and insightful report sheds light on Market Insights of Rare Neurological Disease Treatment, key dynamics, their impact on the overall value chain from suppliers to end-users and Growth of Rare Neurological Disease Treatment Market.

The global rare neurological disease treatment market is segmented on the basis of drug class, route of administration, disease indication, distribution channel, and region.

Need more information about Report Methodology? Click here-https://www.factmr.com/connectus/sample?flag=RM&rep_id=4594

This taxonomy and the detailed TOC prepared are confidential and intended exclusively for the individual or entity with whom it is being shared.

Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.

Country-specific assessment on demand for rare neurological disease treatment has been provided for each regional market, along with the market size valuation and forecast price point assessment, price index and impact analysis of key regional and country-wise dynamics, which were obtained through quotes from numerous rare neurological disease treatment manufacturers, experts, and suppliers.

Y-o-Y growth projections have also been offered on all regional markets incorporated in the report. Moreover, future trends, growth prospects, and other possibilities related to the market have been answered in the report.

The report provides company-level market share analysis, which has been derived on the basis of the companys annual sales and segmental revenue in all the target disease indications. The market has been forecasted based on constant currency rates.

The report provides detailed competitive and company profiles of key participants operating in the global rare neurological disease treatment market.

Some of the key competitors operating in the rare neurological disease treatment market are Novartis AG, Pfizer, Inc., Johnson & Johnson Services, Inc. Bayer AG, GlaxoSmithKline Plc, Sanofi S.A., Allergan Plc, Merck & Co., Inc., and others.

The following report provides forecast and analysis of the global rare neurological disease treatment market along with the historical data of 2013, estimated data 2018 and forecast data up to 2028 in terms of value (US$ Mn), according to a Fact.MR study.

The research propounds critical trends that are currently influencing growth within the global rare neurological disease treatment market along with several macro-economic indicators.

This newly published and insightful report on rare neurological disease treatment sheds light on key dynamics, and their impact on the overall value chain from suppliers to end-users, which are expected to transform the future of the global rare neurological disease treatment market.

The report also comprises the study of current issues with end users and opportunities for rare neurological disease treatment. It also contains value chain analysis, including the key market participants.

To provide users of this report with a comprehensive view of the market, we have included a detailed competitive analysis about the key players involved in the market and strategic overviews.

The dashboard included in the report provides a detailed comparison of rare neurological disease treatment manufacturers on parameters such as total revenue, product offerings, and key strategies.

A list of key companies operating in the rare neurological disease treatment market provided in the report adds to the credibility of this exhaustive research study.

Strategic partnerships between pharmaceutical giants and researchers as well as orphan drug legislations are providing financial incentives for companies developing drugs for rare neurological diseases, Says an Analyst at Fact.MR

Full Access of this Exclusive Report is Available at-https://www.factmr.com/checkout/4594

Report Benefits & Key Questions Answered

More Valuable Insights on Rare Neurological Disease Treatment Market

Fact.MR, in its new report, offers an unbiased Market Analysis of Rare Neurological Disease Treatment, Sales and Demand of Rare Neurological Disease Treatment, analyzing forecast statistics through 2019 and beyond. The study reveals growth projections on the basis of various criteria.

Explore Fact.MRs Comprehensive Coverage on Healthcare Domain:

Fluoro Enzymatic Assays Market Global Industry Analysis and Opportunity Assessment 2021 2031

Shower Chairs MarketGlobal Industry Analysis and Opportunity Assessment 2021 2031

Infrared Thermometer MarketGlobal Industry Analysis and Opportunity Assessment 2021 2031

Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases – Yahoo Finance

Posted on December 8, 2021 by Danzig

LYON, France, December 06, 2021--(BUSINESS WIRE)--POXEL SA (Euronext POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced the formation of its Scientific Advisory Board (SAB) for rare metabolic diseases. The new SAB will initially focus on supporting Poxel's X-linked adrenoleukodystrophy (ALD) program.

"I am delighted to welcome this distinguished group of scientific thought leaders to Poxels SAB for rare metabolic diseases. These therapeutic indications, including ALD, are areas of unsurpassed unmet medical need where treatments are not available or very limited. We are grateful for their informed counsel and deep knowledge and experience that will help shape Poxels discovery and clinical-stage programs and further advance our mission to develop therapies for rare metabolic diseases. We look forward to continuing to collaborate with this accomplished group of advisors as we expand our clinical programs, and initiate Phase 2a studies for ALD in early 2022, with both PXL065, a novel deuterium modified thiazolidinedione and PXL770, a first-in-class direct AMPK activator," said David E. Moller, Poxel's Chief Scientific Officer.

Poxel recently hosted its first SAB meeting on rare diseases, which led to highly productive discussions regarding the potential of its compounds and the future of its programs in ALD, including the design of its two proof-of-concept (POC) Phase 2a studies which the Company intends to initiate early 2022.

The members of the Rare Metabolic Diseases Scientific Advisory Board are the following:

Prof. Florian Eichler, MD, is an expert in inherited diseases with metabolic pathophysiology that affect the nervous system. Dr. Eichler received training in pediatric neurology and neurogenetics at Harvard and Johns Hopkins. He is currently the director of the Center for Rare Neurologic Disorders and the director of the Leukodystrophy Service at Massachusetts General Hospital (MGH), Harvard Medical School, US. His research focus is on the genetics of peroxisomal disorders, lipid metabolism, and gene therapy for neurodegenerative diseases. Dr. Eichler is also President of ALD Connect.

Story continues

Prof. Marc Engelen, MD, PhD, is a clinical researcher, a specialist in pediatric neurology, gastroenterology and endocrinology, and an expert in peroxisomal disorders and leukodystrophies at Amsterdam University Medical Centers, Netherlands. Dr. Engelen received his MD and PhD degrees at the University of Amsterdam. Along with Stephan Kemp and other members of his team, Dr. Engelen's research efforts have unveiled novel approaches to detecting, diagnosing and monitoring neurometabolic diseases including ALD.

Prof. S. Ali Fatemi, MD, is a physician-scientist leader in pediatric neurology and neurometabolic diseases. Dr. Fatemi was trained at the Medical University of Vienna, Austria and at Kennedy Krieger Institute, Johns Hopkins, US. He founded the Moser Center for Leukodystrophies and is now Chief Medical Officer at the Kennedy Krieger Institute, Baltimore, US. His research is focused on basic and translational studies pertaining to the pathophysiology of ALD.

Prof. Stephan Kemp, PhD, is a translational research expert in genetic neurometabolic diseases. He was trained at Johns Hopkins University, Kennedy Krieger Institute, and at the University of Amsterdam, where he is a longstanding faculty member. His research focuses on lipid metabolism and neurotoxicity and he has published many seminal papers on the pathobiology of ALD. He also leads efforts focused on newborn screening for rare metabolic disorders in the Netherlands.

Prof. Fanny Mochel, MD, PhD, is an expert in inborn errors of metabolism. She received training in genetics and neuroscience at University Pierre and Marie Curie in Paris and she is a faculty member in genetics at this university. Dr. Mochel also leads the French reference Center on Neurometabolic diseases and is co-chair of the French society for inborn of errors of metabolism and a council member of the Society for the Study of Inborn Errors of Metabolism. Her research efforts include characterization and treatment of brain energy deficiencies in neurometabolic disease, the identification of novel biomarkers, metabolomics and in vivo metabolic imaging, as well as therapeutic approaches targeting the Krebs cycle.

Dr. Jaspreet Singh, PhD, is a neuroscientist researcher focusing on ALD pathophysiology, neuroinflammation, biomarker development and testing novel therapeutic options. He was trained in India and at the Medical University of South Carolina, US. He is currently a faculty member in the Department of Neurology at the Henry Ford Health System in Detroit, US.

Prof. Keith Van Haren, MD, is a pediatric neurologist and an expert in ALD. He received medical and specialty training at the University of Rochester Medical School, Harvard Medical School, and Stanford University, US. Dr. Van Haren is a faculty member in Neurology and Neurological Sciences at Stanford. He cares for patients including many with ALD and also leads a laboratory focusing on the study of single-gene mutations and attendant molecular mechanisms leading to neuroinflammation in humans.

About ALDX-linked adrenoleukodystrophy (ALD) is an orphan neurometabolic disease caused by mutations in the ABCD1 gene which encodes for a key protein that is required for metabolism of very long chain fatty acids (VLCFA) by peroxisomes (cellular organelles). ALD is the most common leukodystrophy with a prevalence similar to hemophilia up to 1/10,000 individuals in the general population have ALD [https://rarediseases.org]. Forms of this disease include cerebral ALD (C-ALD) and adrenomyeloneuropathy (AMN) which is the most common form typically occurring in adolescence through adulthood. AMN is characterized by chronic and progressive distal axonopathy involving the long tracts of the spinal cord and to a lesser extent the peripheral nerves resulting in progressive stiffness and weakness in the legs, impaired gait and balance, incontinence, and loss of sensation. All men are affected, and many women also present with features of AMN with a later onset. C-ALD is characterized by inflammatory demyelination of cells in the brain and typically afflicts children, but many men with AMN may also develop cerebral disease; these white matter brain lesions lead to severe neurologic deficits and death. There are no approved medicines for ALD (other than glucocorticoid supplements for associated adrenal insufficiency). C-ALD when first detected in early childhood, can be treated with hematopoietic stem cell transplantation. HSCT is currently limited to early stage of C-ALD and this procedure is at risk of severe adverse reactions.

About Poxel SA

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2 trial (DESTINY-1). PXL770, a first-in-class direct AMPK activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH, which met its objectives. For the rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the company intends to initiate Phase 2a proof of concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). TWYMEEG (Imeglimin), Poxels first-in-class lead product that targets mitochondrial dysfunction, has been approved and launched for the treatment of type 2 diabetes in Japan. Poxel expects to receive sales-based payments and royalties from Sumitomo Dainippon Pharma. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: http://www.poxelpharma.com

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Companys control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Companys control that could cause the Companys actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211205005012/en/

Contacts

Poxel SA Catherine DavidInvestor Relations & Communication Managercatherine.david@poxelpharma.com +33 7 64 57 61 78

Aurlie BozzaInvestor Relations & Communication Directoraurelie.bozza@poxelpharma.com +33 6 99 81 08 36

Elizabeth WooSenior Vice President, Investor Relations & Communicationelizabeth.woo@poxelpharma.com

Investor relations / Media NewCapEmmanuel Huynh or Arthur Rouillpoxel@newcap.eu +33 1 44 71 94 94

Go here to read the rest:
Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases - Yahoo Finance

Retired neurologist with Alzheimer’s knows firsthand the risks of Aduhelm – STAT – STAT

Posted on August 3, 2021 by Danzig

Daniel Gibbs had received only four monthly doses of Biogens experimental Alzheimers drug in a clinical trial in 2017 when he ended up in an intensive care unit.He had an excruciating headache, and his blood pressure was so high that doctors thought he might be having a stroke.

It turned out that the retired Portland, Ore., neurologist who had treated Alzheimers patients before he was diagnosed with the disease himself in 2015 was experiencing some of the worst reported side effects of the drug. Doctors prescribed medicines to lower his blood pressure, which reached 206/116, and later to reduce brain swelling. But for weeks afterward, he struggled to read, follow conversations, and do simple math. He recovered but never again took the Alzheimers drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

Continued here:
Retired neurologist with Alzheimer's knows firsthand the risks of Aduhelm - STAT - STAT

Global Neurology Devices Market 2021: SWOT Analysis of Key Driving Factors for Growing CAGR Value | Top Brands: Boston Scientific, Terumo Corporation,…

Posted on November 7, 2021 by Danzig

The latest research report on the Global Neurology Devices Market provides the cumulative study on the COVID-19 outbreak to provide the latest information on the key features of the Neurology Devices market. This intelligence report contains investigations based on current scenarios, historical records and future forecasts. The report contains various market forecasts related to market size, revenue, production, CAGR, consumption, gross margin in the form of charts, graphs, pie charts, tables and more. While emphasizing the main driving and restraining forces in this market, the report also offers a comprehensive study of future trends and developments in the market. It also examines the role of the major market players involved in the industry, including their business overview, financial summary and SWOT analysis. It provides a 360-degree overview of the industries competitive landscape. Neurology Devices Market shows steady growth and CAGR is expected to improve during the forecast period.

The Global Neurology Devices Market Report gives you in-depth information, industry knowledge, market forecast and analysis. The global Neurology Devices industry report also clarifies financial risks and environmental compliance. The Global Neurology Devices Market Report helps industry enthusiasts including investors and decision makers to make reliable capital investments, develop strategies, optimize their business portfolio, succeed in innovation and work safely and sustainably.

Get FREE Sample copy of this Report with Graphs and Charts at:https://reportsglobe.com/download-sample/?rid=131493

Top Key Players Profiled in this report are:

The report is an assortment of direct information, subjective and quantitative assessment by industry specialists, contributions from industry examiners and Neurology Devices industry members over the worth chain. The report offers a top to bottom investigation of parent market patterns, macroeconomic measures, and control components. Besides, the report likewise overviews the subjective effect of unmistakable market factors on Neurology Devices market sections and geologies.

Neurology Devices Market Segmentation:

Based on Type

Based on Application

Global Neurology Devices Market: Regional Segments

The different section on regional segmentation gives the regional aspects of the worldwide Neurology Devices market. This chapter describes the regulatory structure that is likely to impact the complete market. It highlights the political landscape in the market and predicts its influence on the Neurology Devices market globally.

Get up to 50% discount on this report at:https://reportsglobe.com/ask-for-discount/?rid=131493

The Study Objectives are:

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Neurology Devices market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

Some Major Points from Table of Contents:

Chapter 1. Research Methodology & Data Sources

Chapter 2. Executive Summary

Chapter 3. Neurology Devices Market: Industry Analysis

Chapter 4. Neurology Devices Market: Product Insights

Chapter 5. Neurology Devices Market: Application Insights

Chapter 6. Neurology Devices Market: Regional Insights

Chapter 7. Neurology Devices Market: Competitive Landscape

Ask your queries regarding customization at: https://reportsglobe.com/need-customization/?rid=131493

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Website: Reportsglobe.com

See the original post:
Global Neurology Devices Market 2021: SWOT Analysis of Key Driving Factors for Growing CAGR Value | Top Brands: Boston Scientific, Terumo Corporation,...

Neurologist Says Severe Headaches Can Be Long-Lasting COVID-19 Symptom – News On 6

Posted on February 6, 2021 by Danzig

A neurologist said theres another long-lasting symptom of COVID-19: severe headaches.

Dr. Jaclyn Duvall said post-viral headaches are nothing new, but whats different about COVID is how long the headaches last and how intense they can be. Dr. Duvall said without treatment, these headaches can be crippling.

"This can be completely life-changing," Duvall said.

Amber Ostasik is one of Dr. Duvall's patients at Hillcrest's Utica Park Clinic. She suffered severe headaches for months after her COVID-19 diagnosis.

"It was very debilitating," Ostasik said. "I was in and out of urgent care because the pain would get so bad that I didn't know what to do."

Ostasik said she was diagnosed with COVID-19 last June and after a few weeks of recovery thought she was in the clear, but the headaches came back.

"When they came back, they came back with a vengeance. Headaches, that doesnt sum up what I was having. I was having head pain. I mean I couldnt see straight the pain was so bad.By the time I saw Dr. Duvall I was in a desperate place," Ostasik said.

Dr. Duvall said the majority of people with the coronavirus won't experience such serious symptoms, but a growing number of people aren't so fortunate.

"I'd say a vast majority of individuals are actually improving within the first few weeks after recovery, but we are seeing a number of patients that are having these lingering effects, even in Amber's case up to 100 days after experiencing COVID," Dr. Duvall said.

Ostasik recovered after specialized treatment but said when she was first diagnosed with COVID-19, she never expected such severe symptoms to last so long.

"I'm in my mid-thirties, I run marathons, I'll be fine. If I get it, I'll get over it within two weeks," Ostasik thought. "I think it was really eye-opening not just for me, but for everyone around me. This could be potentially life-changing."

Dr. Duvall said if your symptoms also linger well after a COVID diagnosis, you should consider going to a specialist for treatment.

Excerpt from:
Neurologist Says Severe Headaches Can Be Long-Lasting COVID-19 Symptom - News On 6

Once bitten, twice shy: the neurology of why one bad curry could put us off for life – Newswise

Posted on February 15, 2021 by Danzig

Newswise A negative experience with food usually leaves us unable to stomach the thought of eating that particular dish again. Using sugar-loving snails as models, researchers at the University of Sussex believe these bad experiences could be causing a switch in our brains, which impacts our future eating habits.

Like many other animals, snails like sugar and usually start feeding on it as soon as it is presented to them. But through aversive training which involved tapping the snails gently on the head when sugar appeared, the snails' behaviour was altered and they refused to feed on the sugar, even when hungry.

When the team of Sussex Neuroscience researchers led by Dr Ildiko Kemenes looked a little closer, they discovered a neuronal mechanism that effectively reversed the snails' usual response to sugar after the conditioning training had taken place.

Dr Ildiko Kemenes, Reader in Neuroscience in the University of Sussex's School of Life Sciences, explained: "There's a neuron in the snail's brain which normally suppresses the feeding circuit. This is important, as the network is prone to becoming spontaneously activated, even in the absence of any food. By suppressing the feeding circuit, it ensures that the snail doesn't just eat everything and anything. But when sugar or other food stimulus is present, this neuron becomes inhibited so that feeding can commence.

"After the aversive training, we found that this neuron reverses its electrical response to sugar and becomes excited instead of inhibited by it. Effectively, a switch has been flipped in the brain which means the snail no longer eats the sugar when presented with it, because sugar now suppresses rather than activates feeding."

When researchers presented the trained snails with a piece of cucumber instead, they found that the animal was still happy to eat the healthy option - showing that the taps were associated with only the particular type of food they were trained to reject.

George Kemenes, Professor of Neuroscience at the University of Sussex and a senior member of the investigator team, added: "Snails provide us with a similar yet exceptionally basic model of how human brains work.

"The effect of the inhibitory neuron which suppresses the feeding circuit in the snail is quite similar to how, in the human brain, cortical networks are under inhibitory control to avoid 'runaway' activation which may lead to overeating resulting in obesity.

"In our research, the negative experience the snail had with the sugar could be likened to eating a bad takeaway curry which then puts us off that particular dish in future.

"We believe that in a human brain, a similar switch could be happening where particular groups of neurons reverse their activity in line with the negative association of a particular food. "

The research, funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and published inCurrent Biology, also revealed that when the neuron was removed entirely from trained snails, they returned to eating sugar again.

Dr Ildiko Kemenes said: "This suggests that the neuron is necessary for the expression of the learned behaviour and for altering the response to sugar.

"However, we cannot rule out that the sugar-activated sensory pathway also undergoes some changes, so we don't make the assumption that this is all that's happening in the brain."

###

Visit link:
Once bitten, twice shy: the neurology of why one bad curry could put us off for life - Newswise

Ocala neurologist to pay $800K to settle allegations of prescribing unnecessary drugs – Ocala

Posted on August 3, 2021 by Danzig

A lawsuit filed against the Florida Neurological Center, LLC and its owner, Dr. Lance Kim of Ocala, in which the defendants were accused of several fraudulent practices under the False Claims Act, has been partially settled.

Kim and the Florida Neurological Center (FNC), located at 2237 SW 19th Ave. Road, Suite 101, have agreed to pay $800,000 to resolve allegations that Kim prescribed medically unnecessary and unreasonable prescription drugs, according to a press release from the U.S. Attorneys Office for the Middle District of Florida.

The release specifically noted Acthar Gel, a prescription drug that cost the Medicare program around $35,000 for every five-day supply Kim prescribed.

$65 million expansion: Ocala Regional Medical Center celebrates groundbreaking of neuro ICU, CV suites

COVID-19 spike: Marion County's 7-day positivity rate now above 19 percent, CDC says

Things you didn't know about WEC: Secret garden, saddle stools, Journey's keyboardist

The agreement partially resolves the allegations brought against Kim and the center, andthere has been no determination of liability.

The lawsuit was filed in Orlando by Michael Singbush, Andrea Herrera and Harvey Kessler MeyerIV, all former employees of the Florida Neurological Center between 2014 and 2017. Under the False Claims Act, private individuals, or relators, can sue, on behalf of the government, companies and individuals that they believe to be defrauding government programs.

Also under the act, the relators are permitted to receive a share of the recovery, totaling $144,000 in this case.

Florida Attorney General Ashley Moodys office issued a press release on the settlement Tuesday, stating that she is working with federal partners to recover thousands of dollars for Floridas Medicaid program related to the settlement.

The program will receive over $113,000 in restitution from the agreement.

Defrauding Floridas Medicaid program is not a victimless crime, Moody said in the release. It harms the taxpayers of our great state. My Medicaid Fraud Control Unit investigators work hard to protect taxpayers by identifying, investigating and stopping fraud exploiting this taxpayer-funded health care program and recovering lost funds whenever possible.

FNC has served Marion County since 1998, according to its website. It specializes in evaluating and treating neurological disorders such as Alzheimers disease, neuropathy, muscle disorders and sleep disorders.

Kim received his undergraduate degree in biochemistry from Boston University and medical degree from Nova Southeastern University in Fort Lauderdale.

He has worked as a research fellow at the Harvard Medical School/Massachusetts General Hospital, interned in internal medicine at Northwestern University Medical Center and received a residency and fellowship in neurology from the University of Chicago.

Kim is the owner and sole practicing physician of FNC.

In a pretrial statement from May, the plaintiffs had maintained that Kim and FNC violated the False Claims Act (FCA) and that each plaintiff faced retaliation after complaining of the illegal actions.

The relators explained that the basic requirement for reimbursement from Medicare, Medicaid and other government healthcare programs is that services are reasonable and medically necessary. They described various ways in which they believed FNC submitted false claims.

The defendants denied any wrongdoing under the FCA, and the parties agreed to a voluntary dismissal of most of the counts on Tuesday.

The claimsthat each relator faced retaliation for questioning the practices and was either forced to resign or fired are still pending.

FNC and Kim deny any retaliation or that the relators engaged in protected activity, which prevents whistleblowers from retaliation.

FNC also soughtdamagein a counterclaim against Singbush, Herrera and Meyer, alleging unlawful use and disclosure of confidential information about patients, as well as breach of employment agreements. Those claims were dismissed in June.

The U.S. Attorneys Office for the Middle District of Florida reminds that tips about potential fraud, waste, abuse and mismanagement can be reported to the Department of Health and Human Services at 800-HHS-TIPS (800-447-8477).

Contact reporter Danielle Johnson at djohnson@gannett.com.

Read the rest here:
Ocala neurologist to pay $800K to settle allegations of prescribing unnecessary drugs - Ocala

A plea for equitable global access to COVID-19 diagnostics, vaccination and therapy: the NeuroCOVID-19 task Force of the european Academy of neurology…

Posted on January 20, 2021 by Danzig

This article was originally published here

Eur J Neurol. 2021 Jan 18. doi: 10.1111/ene.14741. Online ahead of print.

ABSTRACT

Coronavirus disease 2019 (COVID-19), a multi-organ disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to challenge health and care systems around the globe. The pandemic has disrupted acute neurology services and routine patient care and has impacted the clinical course in patients with chronic neurologic disease. COVID-19 appears to have exposed inequalities of societies and healthcare systems and had disproportionate impact on already vulnerable communities. The next challenge will be to set up initiatives to stop disparities in all aspects related to COVID-19. From the medical perspective, there is a need to consider inequalities in prevention, treatment, and long-term consequences. Some of the issues of direct relevance to neurologists are summarised. With this appraisal, the European Academy of Neurology NeuroCOVID-19 Task Force intends to raise awareness of the potential impact of COVID-19 on inequalities in healthcare and calls for action to prevent disparity at individual, national and supranational level.

PMID:33460486 | DOI:10.1111/ene.14741

Examining the neurological manifestations of COVID-19 – Contemporary Pediatrics

Posted on February 2, 2021 by Danzig

An investigation looks at the neurological manifestations of COVID-19.

Although coronavirus disease 2019 (COVID-19) is first and foremost a respiratory disease, the past year has shown that the disease can also impact other systems in the body, particularly the cardiovascular system. A report in TheLancet Children & Adolescent Health looks at how the disease shows up in neuroimaging.1

The researchers put out an international call to find cases of children who had encephalopathy that was linked to a severe case of COVID-19. They asked for the clinical history as well as association cerebrospinal fluid and plasma data for each case as well. Each case was looked at by a child neurologist, pediatric infectious disease expert, and central neuroradiology panel. Any case that did not have a direct link to a COVID-19 infection was excluded from the study.

A total of 38 children with neurological disease linked to COVID-19 were found in France, the United Kingdom, the United States, Brazil, Argentina, India, Peru, and Saudi Arabia. The researchers found recurring patterns of disease and the neuroimaging abnormalities seen ranged from mild to severe. The most common neuroimaging patterns found were postinfectious immune-mediated acute disseminated encephalomyelitis-like changes of the brain (16 patients), neural enhancement (13 patients), and myelitis (8 patients). Children with multisystem inflammatory syndrome in children were the ones most likely to have splenial lesions (7 patients) and myositis (4 patients). Complications in the cerebrovascular system were not as common among children and adults. No significant pre-existing conditions were seen in children and most of them had favorable outcomes. Four children who previously been healthy before COVID-19 developed fatal atypical central nervous system co-infections.

The researchers concluded that central nervous system abnormalities have been seen in children who had COVID-19. They urged further research to get a better understanding of how the disease can impact the central nervous system as well as provide information on how to provide long-term follow-up care.

Reference

1. Lindan C, Mankad K, Ram D, et al. Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study. Lancet Child Adolesc Health. December 15, 2020. Epub ahead of print. doi:10.1016/S2352-4642(20)30362-X

My wife has a degenerative neurological disease. My father-in-law wants to put her in a facility and take over our finances – MarketWatch

Posted on January 20, 2021 by Danzig

Dear Moneyist,

I have been married for 24 years. My wife and I have two 18-year-old children. We have had our marital ups and downs as many do, but manage to get along. My wife was diagnosed with a terminal degenerative neurological condition.

She grows increasingly frail, both physically and cognitively. Although at times it is not easy, myself and our two children, who are home from school due to the pandemic, care for her the best we can. She lives very comfortably in the home we have owned for 20 years.

The Moneyist:I took care of my late mother for 8 years. Am I obliged to tell my sisters she made me co-owner of a substantial bank account?

My wifes family is largely dysfunctional, and her father abandoned her as a young child, never returning in any meaningful way or providing support aside from cards and perfunctory holiday pleasantries. I do not get along with my father-in-law and have largely avoided him.

Upon learning of my wifes condition, my father-in-law now seems obsessed with moving my wife out of our home to some sort of group home/facility. The mere thought of this seems abhorrent and barbaric. My thinking is that he intends to obtain guardianship and access marital assets, mainly our home, which has substantial value and equity.

My greatest wish is to avoid a bitter legal fight in my wifes last years, and provide her with the best care, medical and otherwise.

Devoted Husband

Want to read more?Follow Quentin Fottrell on Twitterand read more of his columns here

Dear Devoted,

Tell your father-in-law that you have heard his opinion, but now you and your children need to take care of your wife at home together as a family, in your own way, and ask him to respect your wishes. If he continues, tell him that you understand that this is an uncertain and concerning time for all of you, but you would like him to trust you and your family to take care of your wife and his daughter. If that doesnt work, you can say, I now need time and space now to take care of things here. I hope you can give me that. You dont have to answer every call and email.

I also advise you to talk to your wife about officially becoming her health-care proxy, so you will be in control of making any life or death decisions concerning her condition. Alternatively, talk to a lawyer about this. Its smart to have a health-care proxy, no matter how old you are or whether or not youre married, according to Care.com. And a health-care proxy also allows you to designate an alternate, so if you and your spouse are in an accident together you still have control over whos making health-care decisions on your behalf.

Similarly, Leanna Hamill, a family attorney in Hingham, Mass., says, If your parents and spouse disagree about your care, this can cause real problems. The best thing to do is execute a health-care proxy appointing the person you choose as your health care agent and then talking to that person and your other family members about your wishes. (Lawyers want to avoid the kind of legal trauma surrounding the life and death of Terry Schiavo.) Regardless, doctors will turn to your wifes next of kin for any vital decisions that need to be made regarding her care. Thats you.

The Moneyist: My son inherited money after his father was killed in an accident. A woman came forward with another legal heir. What now?

But there is no reason to assume the same will happen here. You will feel less anxious about your father-in-laws interference when you speak up. You dont have to be held hostage to other peoples wishes. Lets assume he wants what he believes is best for his daughter. You simply have a different opinion and approach. He cant force you to sell your home or refinance your home to do something you dont want to do. You are probably under more stress than you realize, and his interference may be a proxy for that stress. It is, perhaps, an obvious if not exactly a useful place to put it.

In the meantime, I recommend seeking out counseling and/or support to help you through this difficult time. The Well Spouse Association is a nonprofit organization that has support groups in communities all over the country. Your wifes condition and comfort is, of course, your No. 1 priority. Dont allow other family members, friends or neighbors to distract you from that. You can only do so much. By creating a support network and healthy boundaries with others however well-meaning they may be I have no doubt that your commitment to your wifes care will be enough.

The Moneyist: My mothers husband died. Her savings are dwindling, yet she pays my sisters bills. Should I intervene?

You can email The Moneyist with any financial and ethical questions related to coronavirus at qfottrell@marketwatch.com

Would you like to sign up to an email alert when a new Moneyist column has been published? If so, click on this link.

Hello there, MarketWatchers. Check out the Moneyist private Facebook FB, +3.87% group where we look for answers to lifes thorniest money issues. Readers write in to me with all sorts of dilemmas. Post your questions, tell me what you want to know more about, or weigh in on the latest Moneyist columns.

Follow this link:
My wife has a degenerative neurological disease. My father-in-law wants to put her in a facility and take over our finances - MarketWatch

Optic Nerve Data Helps Boost Diagnostic Performance Among Patients With MS – Neurology Advisor

Posted on January 20, 2021 by Danzig

Researchers from the Universitat Autnoma de Barcelona in Spain found that incorporating features of the optic nerve into multiple sclerosis (MS) diagnostic criteria improved diagnostic performance by increasing sensitivity without lowering specificity, according to study results published in Neurology.

Data for this study came from a prospective study of 1238 patients diagnosed with clinically isolated syndrome after a single magnetic resonance imaging (MRI) scan performed between 1995 and 2017. Study investigators retrospectively assessed data of visual evoked potentials through patient medical records. They split patients into risk assessment (n=388) and diagnostic criteria performance (n=151) cohorts to validate whether MS diagnostic criteria improved with the addition of optic nerve information.

At clinically isolated syndrome diagnosis, patients were a mean age of 31.6 (standard deviation [SD], 8.2 years). 68% of patients were women; 63.6% had nonoptic neuritis; 58.8% were positive for oligoclonal bands; 71.2% had an abnormal MRI; 37.8% had abnormal visual evoked potentials; and the median extended disability status scale was 1 (range, 0-5.5).

Among cohort 1, persons with higher levels of diagnostic criteria were at increased risk for a second attack from 1 criterion (hazard ratio [HR] 5.6; 95% CI, 1.9-16.5) to 5 criteria (HR 22.7; 95% CI, 7.9-65.7).

The 2017 dissemination in space (DIS) criteria identified a similar risk for second attack (HR, 4.3; 95% CI, 2.8-6.5) as the modified DIS (modDIS) (HR, 4.8; 95% CI, 3.0-7.5). Stratified by optic nerve involvement, the risk for a second attack was projected to be elevated among patients with optic neuritis using the modDIS (HR, 4.3; 95% CI, 1.9-9.6) compared with 2017 DIS (HR, 3.8; 95% CI, 1.8-8.0).

Among cohort 2, identifying the risk for second attack at 10 years according to the 2017 DIS was less precise (sensitivity, 79.2%; specificity, 52.4%; accuracy, 75.5%; positive predictive value [PPV], 91.1%; negative predictive value [NPV], 28.9%) compared with the modDIS (sensitivity, 82.3%; specificity, 52.4%; accuracy, 78.1%; PPV, 91.4%; NPV, 32.3%).

Similarly, among only the patients with optic neuritis, the 2017 DIS predicted a second attack at 10 years with a poorer overall performance (sensitivity, 69.7%; specificity, 57.1%; accuracy, 67.5%; PPV, 88.5%; NPV, 28.6%) compared with the modDIS criteria (sensitivity, 75.8%; specificity, 57.1%; accuracy, 72.5%; PPV, 89.3%; NPV, 33.3%).

This study may have included some selection bias, as researchers included only patients with complete medical records in the 2 cohorts analyzed here.

According to their findings, the study researchers concluded that the addition of the optic nerve to the current DIS criteria slightly increases the accuracy and sensitivity without lowering the specificity, providing additional evidence that argues in favor of including the optic nerve as a new region in the diagnostic criteria.

Disclosure: Multiple authors declared affiliations with industry. Please refer to the original article for a full list of authors disclosures.

Reference

Vidal-Jordana A, Rovira A, Arrambide G, et al. Optic nerve region in multiple sclerosis diagnosis: the utility of visual evoked potentials. Published online December 16, 2020. Neurology. doi:10.1212/WNL.0000000000011339

View original post here:
Optic Nerve Data Helps Boost Diagnostic Performance Among Patients With MS - Neurology Advisor

Select Page ::